Weiss SA, Sznol M, Shaheen M, Berciano-Guerrero MA, et al. A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1. Clin Cancer Res 2023 Aug 3:CCR-23-0475. doi: 10.1158/1078-0432.CCR-23-0475.
PMID: 37535056